Article

FDA approves toric IOL for cataract patients

Fort Worth, TX—The FDA has given Alcon Laboratories Inc. its approval to market the AcrySof toric IOL for use in cataract patients with pre-existing corneal astigmatism.

Fort Worth, TX-The FDA has given Alcon Laboratories Inc. its approval to market the AcrySof toric IOL for use in cataract patients with pre-existing corneal astigmatism.

The new lens is based on the AcrySof single-piece IOL design with the same acrylic material. Its optical design offers improved distance visual outcomes, the company said.

"Approval of the AcrySof toric IOL is an important addition to our AcrySof IOL product portfolio and further demonstrates our commitment to helping cataract surgeons achieve the best possible outcomes," said Robert J. Stevens, vice president, surgical products research and development.

Alcon also said in a prepared statement that it will seek FDA approval of a blue-light-absorbing chromophore to be incorporated into the lens.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.